Continuing Ovarian Suppression After 5 Years
Part of Cancer, Skin clinical trials.
This trial checks if staying on ovarian function suppression (OFS) therapy beyond 5 years helps prevent breast cancer from coming back. It's for women with early-stage, hormone-sensitive (HR+ HER2-) breast cancer who have already completed 5 years of OFS.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have early-stage breast cancer (cancer that hasn't spread far).
- You are a woman between 18 and 60 years old.
- Your cancer is hormone receptor-positive and HER2-negative.
- You have already been on ovarian function suppression (OFS) therapy for 5 years.
- You are in good general health (able to do daily activities with little or no help).
- You agree to join the study and sign a consent form.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how well women stick to their hormone therapy plan after breast cancer surgery. The treatment includes ovarian suppression (to lower estrogen) plus endocrine therapy, and the goal is to see how well it works in real life.
This trial studies the safety of continuing endocrine therapy with ovarian suppression (for women) after you finish the earlier OVELIA study. It may help doctors confirm that the treatment remains safe for longer-term use.
This trial is testing a new treatment plan for women with high-risk breast cancer that is hormone receptor positive (HR+) and HER2 negative (HER2-). It combines radiation therapy after surgery with a CDK4/6 inhibitor, which is a targeted therapy that helps stop cancer cells from dividing. The goal is to see if this combination is safe and well-tolerated, and it may help lower the chance of cancer coming back.
This Phase 3 trial tests whether ongoing treatment with an aromatase inhibitor (a hormone-blocking medicine) after initial chemotherapy can help keep epithelial ovarian/fallopian tube/peritoneal cancer from coming back. It is only for certain tumor types that are hormone-receptor positive (ER+).
This trial tests a new blood test (OCS) that may help detect if ovarian cancer comes back after initial treatment. It is for people whose CA125 levels were normal at diagnosis.
This study checks if a simple blood test can tell whether the monthly hormone injection is working well enough to keep estrogen levels low in young women with early breast cancer. It may help doctors adjust treatment to improve outcomes.
Hear when a new Breast Cancer Female trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.